• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events > Chagas Disease in the Americas: Improving Access and Tools for Patient Diagnosis and Treatment > Page 9

Chagas Disease in the Americas: Improving Access and Tools for Patient Diagnosis and Treatment

2 October 2009

Los Angeles, USA

  • Press releases
    • Overview
    • Symposium
    • Speaker Bios
    • Presentations
    • Symposium Articles
    • Materials
    • Background Papers
    • Campaign Documents
    • Press releases
    • Articles

Press Releases

DNDi Press Release

Eisai and DNDi Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease

Washington, October 1, 2009 — Eisai Co., Ltd. (“Eisai”) and the Drugs for Neglected Diseases initiative (DNDi), a non-profit independent foundation, announced today that they have signed a collaboration and license agreement for the clinical development of a promising new drug for the treatment of Chagas disease, a fatal infectious disease that threatens 100 million people in Latin America and the Caribbean.

Ravuconazole, an anti-fungal drug discovered and developed by Eisai, has been shown in in vitro and in vivo to have potent activity against the pathogen responsible for Chagas disease. Under the terms of the agreement, DNDi shall retain sole responsibility for the clinical development to assess the safety and efficacy of E1224, which is a pro-drug of ravuconazole, in patients with Chagas disease within endemic countries. Eisai shall provide DNDi with its scientific expertise in clinical development as well as supply the drug for the clinical studies. Eisai shall also have the option to become the industrial partner with DNDi to manufacture, register and make available E1224 at an affordable price to the public sector in endemic countries.

Read full press release

MSF Press Release

Neglected Diseases in the Americas: Member States of PAHO Commit to Diagnose and Treat Neglected Diseases at Primary Healthcare Centers.

During the PAHO 49th Directing Council, MSF calls for governments to strengthen mechanisms of procurement for existing medicines so that access to treatment becomes a reality

Washington, October 1, 2009 — The 49th Pan American Health Organization (PAHO) Directing Council is being held in Washington DC this week. The international medical humanitarian organization Médecins Sans Frontières (MSF) welcomes the approved resolution for neglected diseases (CD49/9) entitled “Elimination of neglected diseases and other poverty-related infections”.

“It is clear that there are many diseases that have been silenced and ignored in the Americas, resulting in millions of people suffering and dying of a range of preventable and treatable infectious diseases, including Chagas disease. So it is a positive step forward that Member States have recognized the clear link between poverty and neglected diseases, and that given the current financial crisis, as well as the impact of the influenza A in the region, it is even more important to maintain neglected diseases as a priority.” said Gemma Ortiz Genovese, Senior Advocacy Officer for Neglected Diseases, MSF.

Read full press release

DNDi Press Release

Forgotten and With Few Treatment Options, Chagas Debilitates and Kills

100 years since Chagas disease was discovered, DNDi launches an international campaign “Wake Up. Time to Treat Chagas Disease!” with a call for better medicines and treatment of patients

Rio de Janeiro, July 9, 2009 — One hundred years after the discovery of Chagas disease, 100 million people remain at risk and the disease continues to debilitate and kill the poorest of the poor. Drugs for Neglected Diseases initiative (DNDi) today, alongside Médecins Sans Frontières (MSF), called on governments, scientific community, private sector and civil society to increase their commitment and support for research and development for better health tools (diagnostics and treatments) and improved access.

Read full press release

MSF Press Release

The Fight Against Chagas: Time to Focus on Patients

MSF calls on endemic countries to diagnose and treat Chagas patients; demands more research and development of new medicines, rapid diagnostic and cure tests

Madrid, July 9, 2009 — The international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) today launched a campaign to raise awareness of the parasitic disease Chagas. MSF is calling on countries where the disease is endemic to stop neglecting the disease by moving beyond prevention activities to increased diagnosis and treatment.

Read full press release

MSF/DNDi Media Alert

Medical, Scientific Experts Gather in Los Angeles to Shed Light on Deadly Latin American Disease Now Increasingly Found in the U.S.

Doctors Without Borders/Médecins Sans Frontières and the Drugs for Neglected Diseases initiative will host a series of events on Chagas, a little-known killer disease threatening millions of people in Latin America and increasingly diagnosed in Los Angeles and cities throughout the U.S. Los Angeles County, home to the nation’s only Chagas treatment center and a large at-risk population, is the US focal point for Chagas disease.

  • Public evening panel discussion to raise awareness of Chagas
  • Scientific/medical symposium to highlight urgent need for better diagnosis and treatment

Download media alert

MSF Press Release

Chagas Disease Not Addressed by World Health Assembly

At 100th Anniversary of Discovery, Disease Is Neglected Once Again; Diagnosis and Treatment Scale-up Needed

Barcelona/Geneva, New York, May, 19, 2009 – The World Health Organization (WHO) has cut short its annual health ministers meeting because of influenza A (H1N1) preparations and has postponed discussions about Chagas disease. Much needed progress in diagnosing and treating people for this neglected disease must not be further delayed, warned the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today.

Read full press release

MSF/DNDi Press Release

Call for Scale-up of R&D for Neglected Diseases

Doctors Without Borders and the Drugs for Neglected Diseases initiative Call For Greater Governmental Leadership to Foster Medical Innovation for Millions Suffering from Neglected Diseases

Geneva/New York, February 23, 2009 — The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi) called today for more sustainable funding for research and development (R&D) to tackle deadly, yet neglected diseases, such as sleeping sickness, visceral leishmaniasis, and Chagas disease, that affect millions of people around the world. MSF also announced its renewed operational and financial support to DNDi, a non-profit R&D organization co-founded by MSF and five public and private research institutes in 2003, in response to the urgent need for new treatments and the lack of adequate public leadership in stimulating R&D and medical innovation for neglected diseases.

Read full press release

MSF Statement

The United Nations Economic and Social Council (UN ECOSOC): Philanthropy & the Global Health Agenda

Statement by Sophie Delaunay Executive Director, MSF-USA

This annual Ministerial review focusing on philanthropy and the Global Health Agenda clearly shows recognition of the urgency to address global health challenges. However, this initiative cannot replace the critical need for greater government leadership to stimulate medical innovation for neglected diseases affecting millions in the poorest corners of the world.

Read full statement

Pages: Page 1, Page 2, Page 3, Page 4, Page 5, Page 6, Page 7, Page 8, Page 9, Page 10
Chagas disease

Other events

Loading...
21 May 2025

Geneva, Switzerland

Accelerating neglected tropical disease elimination through country-driven efforts and cross-border collaboration

20 May 2025

Geneva, Switzerland

Strengthening the global ecosystem for paediatric medicines: leadership, collaboration, and impact

21 May 2025

Geneva, Switzerland

Scaling impact: Climate & health solutions that drive change

7-10 May 2025

Amsterdam, The Netherlands

EASL Congress 2025

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License